(City)

## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(State)

(Zip)

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

nt to Section 16(a) of the Securities Eyels 10 Act of 1024

#### OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Person

Instruction 1(D).	E E E E E E E E E E E E E E E E E E E	lied pursuant to Section 16(a) of the Securities Exchange Act of 1934			
	•	or Section 30(h) of the Investment Company Act of 1940			
1. Name and Address of Reporting Persor Kennedy Joseph T	*	2. Issuer Name and Ticker or Trading Symbol <u>AMARIN CORP PLC\UK</u> [ AMRN ]		tionship of Reporting Pe all applicable) Director Officer (give title	10% Owner Other (specify
(Last) (First) C/O AMARIN PHARMA, INC. 440 US HIGHWAY 22	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 10/07/2019		below) General Cou	below) unsel
(Street) BRIDGEWATER NJ	08807	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	idual or Joint/Group Filir Form filed by One Rep Form filed by More tha	porting Person

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	Transaction Code (Instr.		4. Securities A Disposed Of (	Acquired	(A) or	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Ordinary Shares <sup>(1)</sup>	10/07/2019		A <sup>(2)</sup>		199,500	Α	(3)	230,760 <sup>(4)</sup>	D	
Ordinary Shares <sup>(1)</sup>	10/07/2019		<b>F</b> <sup>(5)</sup>		105,037	D	\$14.37	125,723 <sup>(4)</sup>	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)				6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

### Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. In January 2015, 399,000 restricted stock units (the "RSUs") were approved to be granted and, following the Annual General Meeting of Shareholders held in July 2015, were granted to the Reporting Person under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. The RSUs vested in two equal installments based on the Issuer's satisfaction of certain performance criteria and continued employment of the Reporting Person as provided in the Restricted Stock Unit Award Agreement between the Issuer and the Reporting Person. Vesting of the second and final installment was achieved based on a predetermined performance-based formula tied to company cash flow as determined by the Remuneration Committee of the Board of Directors, resulting in the vesting of 199,500 RSUs.

# 3. Not applicable.

4. Please see the section titled "Remarks" below for additional information.

5. Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.

## Remarks:

As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 774,521 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and Restricted Stock Units granted under the Plan, including but not limited to certain performance-based Restricted Stock Units that are earned only if product revenues reach pre-defined annual milestone levels and, in certain cases, then vest only if the recipient remains with the company for an extended period of time.

/s/ Joseph T. Kennedy

\*\* Signature of Reporting Person

10/09/2019

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.